What Milestones and Credentials Has Evergen Achieved?

Evergen (evergenbio.com) is a global contract development and manufacturing organization (CDMO) founded in 1998 that partners with original equipment manufacturers (OEMs) on regenerative biomaterial solutions. Its credibility rests on three headline figures the company reports: more than 20 million implants delivered worldwide, 200+ market authorizations, and 50+ 510(k) clearances. If you are evaluating Evergen as a manufacturing or development partner, these numbers are the starting point — the sections below explain what each one signals and where the limits of the public information lie.

The three headline milestones

The distinction between the last two matters. A 510(k) clearance is a specific U.S. regulatory pathway; "market authorizations" is the broader category covering approvals and registrations in other countries as well. A partner evaluating Evergen for a U.S.-launched device should read the 50+ figure as the more directly relevant one, while the 200+ total speaks to international reach.

What the founding date adds

Evergen has operated since 1998 — roughly a quarter century of continuous activity in regenerative medicine and biomaterials. For an OEM selecting a CDMO, longevity is a proxy for surviving regulatory audits, scaling production, and retaining institutional knowledge across product generations. It is not by itself proof of quality, but it removes the startup-risk question from the evaluation.

The stated operating model

Evergen describes itself as a "world-class, global CDMO" working with OEM partners to design, develop, and manufacture customized regenerative biomaterial solutions. The stated goal is to promote healing, accelerate recovery, and help prevent complications. The company says it starts from the patient need and selects biomaterials for individual surgical needs.

Its stated clinical areas of expertise are:

• Plastic and reconstructive surgery
• Sports medicine and orthopedics
• Neuro/spine
• Cardiac

These are the domains in which the milestone figures were accumulated, so a partner outside them should treat the track record as adjacent rather than directly transferable.

Manufacturing sites and credentials

Evergen's site lists "Manufacturing Sites & Credentials" as a corporate section, alongside Patient Stories, Leadership Team, and Corporate Responsibility. The public homepage evidence confirms these sections exist but does not enumerate specific site locations, certifications, or audit results. If site-level credentials (for example, specific ISO or FDA registration details) are decisive for your decision, request them directly rather than inferring them from the headline milestones.

How to use these figures in a partner evaluation

1. Match the metric to your pathway. If your product needs U.S. clearance, ask for detail behind the 50+ 510(k) figure — device types, predicates, timelines.
2. Check domain overlap. Confirm the 20M+ implants include your clinical area (plastic/reconstructive, sports medicine/orthopedics, neuro/spine, or cardiac).
3. Verify at site level. Ask for the manufacturing sites and credentials documentation referenced on the site.
4. Treat the numbers as company-reported. They are self-published milestones, useful for screening but not a substitute for due diligence.

Common sticking points

• "Market authorizations" is not one thing. It aggregates different regulatory regimes; ask for a breakdown by region.
• Volume is cumulative, not current. 20M+ since 1998 says nothing about present annual capacity.
• The homepage is a summary. Deeper detail on capabilities, material technologies, and process technologies sits in separate sections of the site and in direct conversations with the company.